Merck

Being named one of Fortune’s 100 Best Companies to Work For® three years in a row is an incredible honor—and it’s all thanks to our team around the world who take pride in their work and remain committed to our purpose of saving and improving lives. Every day, we strive to be a workplace of innovation and integrity by investing in the development, growth and well-being of our people. #GreatPlacetoWork From Fortune. ©2025 Fortune Media IP Limited. All rights reserved.

Using the power of leading-edge science, we're taking on some of the world's most pressing health challenges. We’re pushing the boundaries of discovery and believe that science will lead the way. Learn more about our research: http://merck.us/3HpetjJ

We stand in support of the nearly 40,000 people living with pulmonary arterial hypertension (#PAH) in the U.S. and are dedicated to progressing scientific advancements for this rare and life-threatening disease. Learn more: http://merck.us/4iZfJew

Technology is always evolving, but our commitment to patients is unwavering. Hear how we’re using tools like artificial intelligence to help bring more medicines and vaccines to the people who need them. Learn more about how we’re using AI & Machine Learning: http://merck.us/4l2cIMm

We know that medical information can be challenging to navigate. That’s why we’re focusing on making our information more clear, concise and understandable to help people make informed health decisions. Learn more: http://merck.us/4hYjBLW

Our scientists are working to discover and develop medicines for Alzheimer’s disease and other debilitating neurodegenerative disorders, which continue to represent one of the greatest therapeutic challenges of our time. Learn more about our research in Alzheimer’s disease: http://merck.us/4cVKQWj

Today, we announced new data from our Phase 3 trial in pulmonary arterial hypertension (#PAH) at #ACC25. Learn more about our latest cardiovascular update: http://merck.us/4jwxGld

We’re excited to share pivotal Phase 3 data for our investigational subcutaneous #immunotherapy currently under regulatory review in the U.S. and Europe. These findings are being presented today at #ELCC2025. Read more about our latest news: http://merck.us/4iIS2r8

Today’s EC decision represents a significant milestone to help protect against invasive #pneumococcal disease and pneumococcal #pneumonia. Read more: http://merck.us/3E4YHNf

Today, we announced an exclusive license to develop, manufacture and commercialize an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Atherosclerotic cardiovascular disease (#ASCVD) remains the leading cause of morbidity and death around the world. We have a long history of making an impact in #cardiovasculardisease and this agreement will expand and complement our diverse cardio-metabolic pipeline. Learn more: http://merck.us/4kZRmPL